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Abstract 
BACKGROUND: Serum Procalcitonin (PCT) is a biomarker that is frequently used to diagnose an infection. In 
some cases of thoracic malignancy, procalcitonin level appears to increase. However, the role of procalcitonin to 
diagnose malignancy is not certain yet, and the causes have not been known.  
AIM: This study aimed to investigate procalcitonin levels in non-small cell lung cancer patients. 
METHODS: This was an observational study with a cross-sectional design. All lung cancer patients did not 
diagnose based on cytology/histopathology results with no evidence nor were signs and symptoms of infection 
recruited through consecutive sampling. The subtypes of lung cancer include adenocarcinoma, squamous cell 
carcinoma, and large cell carcinoma, staged III and IV. The procalcitonin levels were analysed from blood using 
immunofluorescent assay. Data were then analysed with the Chi-Square test by Epi Info™ 7 programs in which p-
value < 0.05 was considered statistically significant. 
RESULTS: A total of 68 lung cancer patients fulfilled the criteria of this study, 55 men (80.9%) and 13 women 
(19.1%). The highest percentage of cytology/histopathology type found was adenocarcinoma (80.9%), and 60.3% 
of those were diagnosed in stage IV. An increased procalcitonin level (greater than 0.01 ng/mL) occurred in 
80.9% of Non-Small Cell Lung Cancer (NSCLC) patients. It appears that the higher the stage of lung cancer, the 
lower procalcitonin levels would be, although it was not statistically significant. There was no association between 
lung cancer subtype with procalcitonin levels.  
CONCLUSION: An increased level of procalcitonin may be an indication not only for infection but also for Non-
Small Cell Lung Cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Procalcitonin (PCT) is a derivate of calcitonin 
hormones. It is produced primarily in the liver by 
macrophages (Kupffer cells) or neuroendocrine cells 
which are involved in systemic reactions in response 
to endotoxin circulation and inflammatory cytokine 
produced during bacterial or fungal infections [1], [2] 
[3]. The plasma level is associated with the severity of 
the infection [4]. In healthy individuals, PCT levels are 
very low (< 0.1 ng/ml). Procalcitonin has shown the 
importance of distinguishing the diagnosis of cancer 
patients with clinical symptoms of fever and increased 
levels of CRP [5], [6]. On the other hand, recent 
studies showed PCT concentrations at the right level 
with sepsis in patients with an advanced stage of 
cancer [7]. This raises doubts about the role of 
procalcitonin in diagnosing infections in cancer 
patients. 
Patients with malignant diagnoses have a 
high risk of developing infections which are non-
specific clinical signs and the sign of several different 
clinical outcomes, such as drug reactions, actual 
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infections, or paraneoplastic syndromes commonly 
known as 'neoplastic fever' [7]. The PCT values rise 
rapidly at 2-4 hours from the bacterial infection onset. 
PCT has a half-life of 22-24 hours; therefore, this 
concentration can be halved when the infection is 
cured [8]. Although PCT in patients with oncology 
neutropenia fever has been investigated in several 
studies, recent meta-analysis studies failed to define 
its role. Also, Shomalli et al., [9] studied the role of 
PCT as a biomarker to distinguish fever due to 
infection and non-infectious fever in non-neutropenia 
patients with solid tumours and hematologic 
malignancy. They also argued that the increase in 
PCT levels and C-Reactive Protein could also 
increase in malignancy. Several malignancies usually 
show false positive for PCT.  
Information about the values and 
characteristics of PCT are limited to lung cancer 
incidence [10]. Based on the above description, this 
study aimed to investigate the procalcitonin levels in 
non-small cell lung cancer patients.  
 
 
Material and Methods 
 
This was an observational study with a cross-
sectional design to investigate the characteristics of 
procalcitonin levels in non-small cell lung cancer 
patients among Indonesia population. The study was 
conducted in Adam Malik General Hospital for 3 
months. Data were collected through the medical 
records of Adam Malik General Hospital from 
November 2016 to June 2017. 
Subjects were recruited through consecutive 
sampling based on cytology/histopathology result. 
Patients diagnosed with tumour mediastinum and lung 
tumour metastasis were excluded from this study. 
Smoking status was also recorded. Patients 
categorised as active smokers if they have a smoking 
history of ≥ 100 cigarettes throughout their lives [11], 
passive smoker (a person who inhales cigarette 
smoke from a smoker). Type of cigarettes includes 
clove cigarettes (kretek) and filter (white) cigarettes. 
The Brinkman Index value was obtained from the 
multiplication of the average number of cigarettes 
smoked a day and multiplied by the duration of 
smoking (years). The value of Brinkman Index (IB) is 
mild if 0-199, moderate if 200-599, and severe if > 600 
[12]. 
First, 4 ml of peripheral venous blood were 
taken and then inserted into the EDTA tube. Next, the 
serum was isolated. The procalcitonin values were 
determined by immunofluorescence using BRAHMS 
procalcitonin sensitive Kryptor automated system 
(Thermo Scientific, Brahms, Henningsdorf, Germany) 
[10]. The values of serum procalcitonin were 
determined, in which levels above 0.01 ng/ml was 
considered high [10]. 
To assess the relationship between gender, 
age, and the Brinkman index with procalcitonin levels 
in non-small cell lung cancer patients, the Chi-Square 
test was performed. While the procalcitonin levels 
based on the cytologic/histopathologic subtypes 
cancer stage were analysed with Mann-Whitney and 
Kruskal Wallis test, data were analysed using Epi 
Info™ 7 programs in which p-value of < 0.05 was 
considered statistically significant. 
 
 
Results 
 
Based on the characteristics of the subjects, it 
was found that the highest number of gender in lung 
cancer incidence was male (80.9%). The average age 
dominant with lung cancer was 40–60 years (51.5%). 
All subjects were smokers and mostly categorised as 
heavy smoker based on Brinkman index (75%). The 
most common subtype of lung cancer was 
adenocarcinoma type (80.9%). The data can be seen 
in Table 1. 
Table 1: Demographic characteristics of the study subjects 
Characteristics n % 
Gender 
Male 55 80.9 
Female 13 19.1 
Age 
Under 40 years-old 3 4.4 
40-60 years-old 35 51.5 
Over 60 years old 30 44.1 
Smoking status 
Active smoker 68 100.0 
Non smoker 0 0.0 
Type of cigarettes 
Clove cigarettes (kretek) 44 64.7 
Filter cigarettes (white) 24 35.3 
Brinkman Index 
Severe 51 75.0 
Moderate 14 20.6 
Mild 3 4.4 
Cytology/histopathology 
Adenocarcinoma 55 80.9 
Squamous Cell Carcinoma 12 17.6 
Large Cell Carcinoma 1 1.5 
pTNM 
I 8 11.8 
II 10 14.7 
III 9 13.2 
IV 41 60.3 
Procalcitonin levels 
Increased (> 0.01 ng/ml) 55 80.9 
Normal ( 0.01 ng/ml) 13 19.1 
 
The association between procalcitonin levels 
and gender, age and Brinkman index on Non-Small 
Cell Lung Cancer patients were displayed in table 2.  
Table 2: The association between demographic factors and the 
levels of procalcitonin 
Variables 
Procalcitonin level 
p-value Increased Normal 
n % n % 
Sex 
Male 44 80.0 11 84.6 
0.702
a 
Female 11 20.0 2 15.4 
Age 
Under 40 years-old 2 3.6 1 7.7 
0.53
a 
40-60 years-old 30 54.5 5 38.5 
Over 60 years old 23 41.8 7 53.8 
Brinkman Index 
Severe 40 72.7 11 84.6 
0.38
a 
Moderate 13 23.6 1 7.7 
Mild 2 3.6 1 7.7 
Total 55 100.0 13 100.0 
 a) Chi-Square test. 
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Table 3 showed that there was no difference 
in the levels of procalcitonin between 
adenocarcinoma, squamous cell carcinoma, and large 
cell carcinoma. It appears that the higher the stage of 
lung cancer, the lower procalcitonin levels would be. 
However, this correlation was not observed in stage 
IV cancer patients, and thus it was not statistically 
significant.  
Table 3: The comparison of procalcitonin levels based on 
tumour diagnosis 
Variables n 
Procalcitonin levels  
mean ± SD median (min-max) p value 
Cytology/ 
histopathology 
Adenocarcinoma (n = 55) 1.02 ± 2.06 0.34 (0.02 - 11.9) 
0.206 
a
 
Squamous Cell 
Carcinoma and large 
cell 
(n = 13) 0.91 ± 1.24 0.48 (0.14 - 4.2) 
Stage I (n = 8) 1.21 ± 2.23 0.44 (0.02 - 6.71) 
0.12
 b
  
II (n = 10) 0.84 ± 0.45 0.90 (0.14 - 1.47) 
 
III (n = 9) 0.63 ± 1.04 0.17 (0.04 - 2.86) 
  IV (n = 41) 1.07 ± 2.24 0.25 (0.02 - 11.9) 
a) Mann-Whitney test; b) Kruskal Wallis test. 
 
Generally, it can be concluded that there was 
no effect of the cancer cell types nor cancer stage on 
serum procalcitonin levels. 
 
 
Discussion 
 
The sample of this research was 68 cases of 
lung cancer patients who have been diagnosed 
definitively (cytology/histopathology). Based on the 
gender of the subjects, there were 55 male patients 
(80.9%) whereas there were 13 female patients 
(19.1%). The same situation was also reflected in 
other parts of the world. Aareleid conducted 
epidemiological studies of lung cancer from 1985 to 
2014. According to that study, 18,399 cases (80.3%) 
were male patients whereas 4491 cases (19.7%) were 
female patients [13]. In Indonesia, specifically in Adam 
Malik General Hospital, Medan, the highest number of 
patients based on gender was male with 85.62% 
compared to a female with 24 patients (24.37%) [3]. 
In this study, the number of patients between 
the age of 40-60 years were predominant with 36 
patients (51.4%), followed by the age group of over 60 
years with 30 patients (42.9%). An epidemiological 
study conducted by Ridge in 2015 also suggested that 
about 60% of lung cancer cases were suffered by 
patients aged 50-60 years old [14]. In his study, he 
also stated that the prevention of cigarettes was a top 
priority for public health. Globally, cigarettes are one 
of the biggest death factors with a 1:10 ratio in adults 
and a mortality rate of about 5 million people per year 
[14]. Similarly, a study conducted by Soeroso in 2018 
showed that 60% of lung cancer cases suffered by 
patients aged 55-64 years [15], [16]. 
Brinkman index is used to assess the severity 
level of smoking. The Brinkman index in this study 
found that 75.7% of subjects were heavy smokers, 
20% were moderate smokers, and the other 4.3% 
were light smokers. A similar result was also found by 
Soeroso et al., [15], [16] in which 52.9% of their 
research participants were categorised as heavy 
smokers. Also, this study was to evaluated nicotine 
dependence based on the Fagerstrom Tolerance 
Questionnaire (mFTQ), and the results showed that 
65% of Fagerstrom scores were very high. 
Epidemiologic studies suggest that smoking is the 
leading cause of lung cancer. Smokers are 22 times 
more likely to die of lung cancer than nonsmokers [1]. 
Smoking has a role in lung cancer at various levels. 
Smoking can cause mutations of genes that leads cell 
to be oncogenic. One of the mutations is a p53 
mutation found in more than 53% in smokers [2]. 
Furthermore, smoking can also influence adverse 
effects during therapy, either chemotherapy or 
radiotherapy [2]. 
Lung cancer is one of the leading causes of 
death around the world, particularly in Indonesia. In 
2014, WHO stated that the mortality rate due to lung 
cancer reached 21.8% for men and 9.1% for a woman 
in Indonesia [17]. The most common type of cancer 
found in this study was adenocarcinoma (80.9%). 
Although previous studies found that squamous cell 
carcinoma as the most common type found, new 
paradigm depicted that adenocarcinoma was the most 
common type of cancer. This is probably because the 
type of cigarettes favoured by Indonesians is clove 
cigarettes. This study found that the most common 
type of lung cancer found in Batak tribe in Indonesia 
was adenocarcinoma (92.9%), and the most 
consumed cigarette type was clove cigarettes. Clove 
cigarettes contain clove that will make smokers suck 
in more deeply; thus, smokes containing carcinogenic 
substances eventually enter the peripheral respiratory 
tract [16], [18]. Syahruddin et al., [19] found that the 
EGFR mutations rate among Indonesian population 
reached 57.1% common mutations (exon 19 ins/dels, 
L858r) and about 29% uncommon mutations (G719X, 
exon 20 ins, T790M, L861Q). 
In this study, most of the patients have 
entered the stage IV of cancer (60%), and the patients 
in stage III were 14.3%. This is slightly different from 
the results found by Soeroso in 2010-2012 in which 
most of the cases were in stage III with 56 cases 
(33.54%) from a total of 167 patients [3]. However, 
there is a trend found that lung cancer is generally 
diagnosed when it has entered an advanced stage. 
There are some factors that may cause late diagnosis. 
One of them is the absence of accurate screening to 
date [4]. 
The results showed that serum procalcitonin 
based on histopathology (adenocarcinoma, squamous 
cell, and large cell) in this study did not show a 
significant difference in the Kruskal-Wallis test (p > 
0.05). This study also showed that the values of 
procalcitonin increased in 55 samples (80.9%). This 
contrasts with Avrillon’s findings that 42% of 89 
samples experienced an increase in procalcitonin 
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levels [10]. Procalcitonin is not a substance commonly 
used as a diagnostic tool for cancer, but recent 
research conducted by Vincenzi et al., [5] showed an 
increased in procalcitonin levels with cancerous 
conditions. The study also stated that during an 
advanced stage of cancer, the production of 
inflammatory cytokines is more active than usual 
leading to procalcitoninemia conditions [5]. 
Ghillani et al., [20] found an increased level of 
procalcitonin compared with healthy subjects by 
17.5%, 53%, and 29% respectively in patients with 
squamous cell cancer, large cell, and 
adenocarcinoma. Non-cancer patients had low 
procalcitonin levels in average compared with patients 
with stage I-III cancer (0.029 ng/mL vs 0.127 ng/mL, p 
< 0.0001) or the stage IV disease (0.029 ng/mL vs 
0.190 ng/mL, p < 0.0001). Cancer patients who have 
accelerated developmental stage have a higher mean 
of PCT than those in the low stages (0.190 ng/mL vs 
0.127 ng/mL, p = .004) [21]. However, the patients in 
severe stages had an increase in the PCT values 
baseline compared with the patients in low stages 
(0.47 vs 0.27 ng/mL), p = 0.017) [9]. The PCT values 
were higher in the patients with small cell lung cancer 
than adenocarcinoma (0.33 ng/mL vs 0.07 ng/mL, p < 
0.001). Furthermore, the PCT levels were significantly 
higher in the patients with liver metastasis (0.37 vs 
0.09 ng/mL, p < 0.001) [22]. Another study showed an 
increase in PCT associated with metastatic stage 
cancer in 43 patients with solid tumour and 15 healthy 
control subjects; the highest level was found in 
metastatic cancer [23]. Also, it was found that 
procalcitonin levels were high in colorectal cancer. 
Keramidaris et al., [6] studied the relationship between 
bacterial translocation and cancer condition and found 
PCT positive in the majority of their samples (55.3%), 
higher procalcitonin levels were also found in 
metastatic patients than no metastasis (p = 0.01). 
One of the limitations of this study was 
incomplete medical records data, especially data of 
lung cancer patients undergoing distant metastasis. 
Therefore, the relationship between procalcitonin 
levels and lung cancer patients undergoing metastasis 
cannot be assessed. Also, this study did not conduct 
C-reactive protein examination in all lung cancer 
patients due to health insurance limitations in 
Indonesia. 
In conclusion, an increased level of 
procalcitonin was observed in most patients with Non-
Small Cell Lung Cancer. It appears that the higher the 
stage of lung cancer, the lower procalcitonin levels 
would be, although it was not statistically significant. 
There was no association between lung cancer 
subtype with procalcitonin levels.  
An increased level of procalcitonin may raise 
a suspicion for Non-Small Cell Lung Cancer, 
particularly if no evidence of infection was found.  
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